Summary
Oncobiologics Inc (Oncobiologics) is a biopharmaceutical company that develops, manufactures and commercializes monoclonal antibodies biosimilars in the therapeutic areas of oncology and immunology. The company's ONS-3010 is a biosimilar of Humira; and ONS-1045 is a biosimilar of Avastin, which is of Phase I trial and Phase 3 trial. Its single-use technology minimizes manufacturing footprint, and reduces utility requirements. Oncobiologics’ products are used in the treatment of rheumatoid arthritis, ulcerative colitis, Crohn’s disease, psoriasis, colorectal cancer, lung cancer, non-hodgkins lymphoma, breast cancer and head and neck cancer. The company collaborates with pharmaceutical, biotechnology, healthcare and various other industries for its clinical development programs. Oncobiologics is headquartered in Cranbury, New Jersey, the US.
Oncobiologics Inc (ONSIU) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Oncobiologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Oncobiologics Raises Additional USD13 Million in Venture Financing 11
Oncobiologics Raises USD31 Million in Financing Round 13
Partnerships 15
Oncobiologics Enters into Agreement with Liomont to Develop Biosimilar Monoclonal Antibody Products 15
Oncobiologics And inVentiv Health Enter Into Agreement To Develop Biosimilars 16
Oncobiologics Enters Into Co-Development Agreement With Zhejiang Huahai Pharma 18
Viropro Enters Into Agreement With Oncobiologics For Biosimilar Monoclonal Antibody Products 20
Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 22
Oncobiologics Enters into Research Agreement with Selexis 23
Oncobiologics Enters Into Co-Development Agreement With Fox Chase Cancer Center 24
Licensing Agreements 26
Ipca Labs Enters into Licensing Agreement with Oncobiologics 26
Oncobiologics Exercises Option for Licensing Agreement with Selexis for ONS-1045 27
Oncobiologics Exercises Option for Licensing Agreement with Selexis for ONS-1050 29
Oncobiologics Exercises Option for Licensing Agreement with Selexis for ONS-3010 31
Oncobiologics Enters Into Licensing Agreement With Boston Oncology For Biosimilar Therapies 33
Oncobiologics Enters Into Licensing Agreement With Parilis BioPharma 34
Equity Offering 35
Oncobiologics Raises USD35 Million in IPO of Units 35
Oncobiologics to Raise USD5 Million in Private Placement of Units 37
Strides Arcolab Invests in Oncobiologics 38
Oncobiologics Inc - Key Competitors 39
Key Employees 40
Locations And Subsidiaries 41
Head Office 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42
List of Tables
Oncobiologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Oncobiologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Oncobiologics Inc, Deals By Therapy Area, 2010 to YTD 2016 8
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Oncobiologics Raises Additional USD13 Million in Venture Financing 11
Oncobiologics Raises USD31 Million in Financing Round 13
Oncobiologics Enters into Agreement with Liomont to Develop Biosimilar Monoclonal Antibody Products 15
Oncobiologics And inVentiv Health Enter Into Agreement To Develop Biosimilars 16
Oncobiologics Enters Into Co-Development Agreement With Zhejiang Huahai Pharma 18
Viropro Enters Into Agreement With Oncobiologics For Biosimilar Monoclonal Antibody Products 20
Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 22
Oncobiologics Enters into Research Agreement with Selexis 23
Oncobiologics Enters Into Co-Development Agreement With Fox Chase Cancer Center 24
Ipca Labs Enters into Licensing Agreement with Oncobiologics 26
Oncobiologics Exercises Option for Licensing Agreement with Selexis for ONS-1045 27
Oncobiologics Exercises Option for Licensing Agreement with Selexis for ONS-1050 29
Oncobiologics Exercises Option for Licensing Agreement with Selexis for ONS-3010 31
Oncobiologics Enters Into Licensing Agreement With Boston Oncology For Biosimilar Therapies 33
Oncobiologics Enters Into Licensing Agreement With Parilis BioPharma 34
Oncobiologics Raises USD35 Million in IPO of Units 35
Oncobiologics to Raise USD5 Million in Private Placement of Units 37
Strides Arcolab Invests in Oncobiologics 38
Oncobiologics Inc, Key Competitors 39
Oncobiologics Inc, Key Employees 40
List of Figures
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
